Tarceva: Uses, Dosage & Side Effects
Erlotinib – an oral EGFR tyrosine kinase inhibitor for the treatment of EGFR-mutation-positive non-small cell lung cancer and metastatic pancreatic cancer
Tarceva (erlotinib) is an orally administered targeted cancer therapy belonging to the class of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. It was one of the first small-molecule EGFR inhibitors to receive regulatory approval and remains an important treatment option for selected patients with non-small cell lung cancer (NSCLC) and metastatic pancreatic cancer. In NSCLC, Tarceva is used as first-line treatment of tumors harbouring activating EGFR mutations, as maintenance therapy after platinum-based chemotherapy, and in later lines after chemotherapy failure. In pancreatic cancer, it is combined with gemcitabine as first-line treatment of metastatic disease. Tarceva is taken once daily as a film-coated tablet (25 mg, 100 mg, or 150 mg) on an empty stomach, and requires specialist oncology supervision due to its potential for serious side effects, drug interactions, and the need for molecular testing in lung cancer.
Quick Facts: Tarceva
Key Takeaways
- Tarceva (erlotinib) is an oral EGFR tyrosine kinase inhibitor that blocks cancer cell growth signals by binding to the intracellular kinase domain of the EGFR receptor, causing cancer cells to stop dividing and undergo apoptosis.
- For non-small cell lung cancer, first-line use requires a confirmed activating EGFR mutation (typically exon 19 deletion or L858R point mutation); in these patients, Tarceva produces response rates of 58–83% and significantly prolongs progression-free survival compared with chemotherapy.
- Tarceva must be taken once daily on an empty stomach (at least 1 hour before or 2 hours after food); taking it with food nearly doubles drug exposure and substantially increases the risk of toxicity.
- The most common side effects are acneiform rash (affecting about 75% of patients) and diarrhea; rare but serious side effects include interstitial lung disease, severe hepatotoxicity, gastrointestinal perforation, and corneal disorders.
- Patients must stop smoking before and during treatment because tobacco smoke induces CYP1A2 and reduces erlotinib plasma concentrations by up to 60%, potentially compromising efficacy; multiple drug interactions (CYP3A4 modulators, acid-reducing agents) also affect drug levels.
What Is Tarceva and What Is It Used For?
Tarceva contains erlotinib, a reversible small-molecule inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR, also known as HER1 or ErbB1). EGFR is a transmembrane receptor expressed on the surface of many normal and malignant cells. When activated by its ligands (such as EGF or transforming growth factor alpha), EGFR triggers a cascade of intracellular signaling events via the RAS/RAF/MEK/ERK and PI3K/AKT pathways. These signals promote cell proliferation, differentiation, survival, angiogenesis, and invasion. In many cancers – most notably certain lung adenocarcinomas – EGFR is either overexpressed or carries activating mutations that render the receptor constitutively active, driving uncontrolled tumour growth.
Erlotinib competes with adenosine triphosphate (ATP) for binding to the intracellular catalytic domain of EGFR. By occupying the ATP-binding pocket, erlotinib prevents autophosphorylation of the receptor’s tyrosine residues, which are essential for downstream signal transduction. The result is a profound inhibition of the oncogenic signals that drive cancer cell growth and survival. Tumours that depend on aberrant EGFR signalling – particularly NSCLC tumours harbouring activating mutations in exons 19 (deletions) or 21 (L858R substitution) of the EGFR gene – are especially sensitive to this blockade and often undergo dramatic, rapid tumour shrinkage when exposed to erlotinib.
Tarceva was developed in the late 1990s and early 2000s and represents one of the first successful examples of molecularly targeted therapy in oncology. It received approval from the U.S. Food and Drug Administration (FDA) in November 2004 for previously treated locally advanced or metastatic NSCLC, based on the pivotal BR.21 trial conducted by the National Cancer Institute of Canada. Subsequent approvals expanded its use to pancreatic cancer (2005, in combination with gemcitabine) and, following the advent of routine EGFR mutation testing, to first-line therapy of EGFR-mutation-positive NSCLC. Tarceva is authorised by the European Medicines Agency (EMA), the FDA, and regulatory agencies worldwide.
Non-Small Cell Lung Cancer (NSCLC)
Non-small cell lung cancer is the most common form of lung cancer, accounting for approximately 85% of cases. Within NSCLC, adenocarcinoma is the most frequent histology, and it is in this subtype that activating EGFR mutations are most commonly found – particularly in never-smokers, women, and patients of East Asian descent (in whom prevalence can exceed 40%). In European and North American populations, activating EGFR mutations are identified in approximately 10–15% of patients with non-squamous NSCLC.
Tarceva is approved in NSCLC for three distinct clinical settings. First-line therapy of locally advanced or metastatic NSCLC with EGFR-activating mutations was established by the landmark EURTAC trial (Rosell et al., Lancet Oncology 2012), which demonstrated a significant improvement in progression-free survival (9.7 vs. 5.2 months, hazard ratio 0.37) in favour of erlotinib compared with standard platinum-doublet chemotherapy in European patients. Response rates in EGFR-mutation-positive NSCLC typically range from 58% to 83%, and quality-of-life benefits over chemotherapy are substantial.
As maintenance therapy, Tarceva is indicated in patients with locally advanced or metastatic NSCLC whose disease has not progressed after 4 cycles of standard platinum-based first-line chemotherapy. This indication was supported by the SATURN trial (Cappuzzo et al., Lancet Oncology 2010), which showed that immediate maintenance with erlotinib prolonged progression-free and overall survival compared with placebo, with the benefit most pronounced in patients harbouring EGFR mutations. In the second- or third-line setting, Tarceva is indicated for locally advanced or metastatic NSCLC after the failure of at least one prior chemotherapy regimen. The pivotal BR.21 trial (Shepherd et al., New England Journal of Medicine 2005) randomised 731 patients with previously treated NSCLC to erlotinib 150 mg daily or placebo, demonstrating a statistically significant improvement in overall survival (6.7 vs. 4.7 months, hazard ratio 0.70, p<0.001).
Metastatic Pancreatic Cancer
Pancreatic ductal adenocarcinoma remains one of the most difficult cancers to treat, with a 5-year overall survival under 10% at the metastatic stage. Tarceva is approved in combination with gemcitabine for first-line treatment of metastatic pancreatic cancer. This indication derives from the phase III PA.3 trial (Moore et al., Journal of Clinical Oncology 2007), which randomised 569 patients with locally advanced or metastatic pancreatic cancer to gemcitabine plus erlotinib (100 mg/day) or gemcitabine plus placebo. The addition of erlotinib produced a modest but statistically significant improvement in overall survival (median 6.24 vs. 5.91 months, hazard ratio 0.82, p=0.038) and in 1-year survival (23% vs. 17%). Clinically meaningful benefits are most often seen in patients who develop an erlotinib-induced skin rash within the first 4–8 weeks, and the overall pancreatic-cancer indication is used selectively in clinical practice in light of newer combination regimens (e.g. FOLFIRINOX, nab-paclitaxel plus gemcitabine).
What Tarceva Is Not Used For
Tarceva is not effective against cancers that do not rely on EGFR signalling. In squamous-cell lung cancers and in non-squamous NSCLC without an activating EGFR mutation, the benefit from erlotinib is small and is generally outweighed by toxicity; in such patients, chemotherapy, immunotherapy, or other targeted agents are preferred. It is also not indicated for small cell lung cancer, colorectal cancer, head and neck cancer, or other solid tumours outside its approved indications. Routine EGFR mutation testing on tumour tissue (or, when tissue is unavailable, on circulating tumour DNA from a blood sample) is therefore essential before starting first-line Tarceva in NSCLC.
Unlike traditional chemotherapy, which damages DNA or microtubules in all rapidly dividing cells, Tarceva is a molecularly targeted therapy. It specifically blocks an abnormal signalling protein that cancer cells depend on for growth. This selectivity generally results in a different side-effect profile – less hair loss, less bone marrow suppression, and less nausea than chemotherapy, but more skin rash, diarrhea, and occasionally more serious lung or liver toxicity. The clinical benefit is greatest when the tumour depends on the target being blocked, which is why EGFR mutation testing is essential before first-line use in NSCLC.
What Should You Know Before Taking Tarceva?
Contraindications
There are specific clinical circumstances in which Tarceva must not be used. Your oncologist will evaluate these before prescribing the drug.
- Hypersensitivity: Tarceva must not be taken by anyone with a known hypersensitivity (allergy) to erlotinib or to any of the excipients in the tablet, including lactose monohydrate.
- Severe hepatic impairment: Erlotinib undergoes extensive hepatic metabolism, and patients with severe liver dysfunction may have markedly elevated drug concentrations. Use in severe hepatic impairment (total bilirubin >3 times the upper limit of normal) is generally contraindicated outside of expert dose-modified regimens.
- Pregnancy: Tarceva is contraindicated during pregnancy due to evidence of embryotoxicity and fetal harm in animal studies.
- Breastfeeding: Breastfeeding must be stopped during treatment and for at least 2 weeks after the last dose, as erlotinib may be excreted in human milk.
Warnings and Precautions
Rare but potentially fatal cases of interstitial lung disease, including acute interstitial pneumonitis, have occurred in patients treated with erlotinib. The reported incidence is approximately 1% worldwide (higher in Japanese populations). Symptoms include new or worsening shortness of breath, dry cough, and fever, often appearing within the first month of therapy. If ILD is suspected, Tarceva must be stopped immediately pending investigation (chest CT, infection work-up); if confirmed, the drug should be permanently discontinued and corticosteroid therapy considered. Contact your medical team urgently if you develop unexplained respiratory symptoms.
Before starting and during treatment with Tarceva, tell your doctor or nurse if any of the following apply to you:
- Lung disease: Pre-existing interstitial lung disease, pulmonary fibrosis, or previous radiation pneumonitis may increase the risk of ILD during erlotinib therapy. Baseline chest imaging and pulmonary assessment may be recommended.
- Liver disease: Hepatitis (including fatal cases) and hepatorenal syndrome have been reported. Liver function tests should be performed at baseline and periodically during treatment (e.g. every 4–8 weeks). More frequent monitoring is advisable in patients with known liver disease or Gilbert’s syndrome, in whom bilirubin elevations are more common.
- Kidney problems: Acute kidney injury and hepatorenal syndrome have been observed, particularly in the context of dehydration from diarrhea or vomiting. Renal function should be monitored, and prompt rehydration is essential if gastrointestinal toxicity occurs.
- Gastrointestinal disease: Rare cases of gastrointestinal perforation, sometimes fatal, have been reported. Patients at higher risk include those with concomitant use of anti-angiogenic agents (e.g. bevacizumab), corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), taxane chemotherapy, or a history of peptic ulcer disease or diverticular disease.
- Eye disorders: Keratitis, corneal ulceration, and rarely corneal perforation have occurred. Patients wearing contact lenses or with a history of severe dry eye are at increased risk. Report any eye pain, redness, blurred vision, or intolerance of light promptly; an ophthalmology assessment may be needed.
- Skin reactions: Severe bullous, blistering, and exfoliative skin reactions, including cases resembling Stevens-Johnson syndrome and toxic epidermal necrolysis, have rarely been reported. The common acneiform rash, by contrast, is usually mild to moderate and manageable with skin-care measures or topical/oral antibiotics.
- Bleeding disorders / anticoagulation: International Normalised Ratio (INR) elevations and bleeding have been reported in patients on warfarin. Close INR monitoring is required when warfarin and Tarceva are used concurrently.
Smoking and Tarceva
Cigarette smoking induces the hepatic enzyme CYP1A2, which metabolises erlotinib. Active smokers have plasma erlotinib concentrations up to 50–60% lower than non-smokers at the same dose, which may reduce the drug’s anti-cancer effectiveness. Patients are strongly advised to stop smoking before starting Tarceva and to remain abstinent throughout treatment. If a patient cannot stop smoking, a dose increase may be considered under specialist supervision, but smoking cessation is always preferred because tobacco also worsens cancer outcomes and treatment tolerability.
Pregnancy, Breastfeeding, and Fertility
Erlotinib has caused embryo-fetal toxicity in animal studies, with reduced fetal/placental weight and increased embryonic or fetal lethality. Tarceva must not be used during pregnancy. A pregnancy test is recommended before starting treatment in women of childbearing potential.
Women of childbearing potential must use highly effective contraception during treatment with Tarceva and for at least 2 weeks after the last dose. If pregnancy occurs during therapy, stop Tarceva immediately and inform your oncologist.
Breastfeeding is contraindicated during treatment and for at least 2 weeks after the last dose. It is unknown whether erlotinib is excreted in human breast milk, and the potential risk to the infant is considered unacceptable.
The effects of erlotinib on human fertility are not fully characterised. Animal studies suggest no significant impact on fertility at clinically relevant doses, but male patients planning to father children should discuss fertility preservation options (such as sperm banking) with their physician before starting treatment.
Children and Adolescents
The safety and efficacy of Tarceva in children and adolescents under 18 years of age have not been established. The drug is not recommended for use in the paediatric population.
Driving and Operating Machinery
No studies of the effect of Tarceva on the ability to drive or operate machinery have been performed. Erlotinib is not known to cause sedation or directly impair cognition, but individual patients may experience fatigue, dizziness, or visual disturbance. Do not drive or use heavy machinery if you feel unwell or if your vision is affected.
Important Information About Excipients
Tarceva film-coated tablets contain lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take Tarceva. Other excipients include microcrystalline cellulose, sodium starch glycolate, sodium lauryl sulfate, and magnesium stearate; none of these are typically relevant for patients unless a specific hypersensitivity is known.
How Does Tarceva Interact with Other Drugs?
Erlotinib is extensively metabolised in the liver, predominantly by cytochrome P450 3A4 (CYP3A4) and, to a lesser extent, by CYP1A2 and CYP1A1. Any agent that significantly inhibits or induces these enzymes, or that alters gastric pH (which influences erlotinib solubility), can change erlotinib plasma concentrations and therefore affect both efficacy and toxicity. It is essential to give your oncologist a complete list of every prescription medicine, over-the-counter product, vitamin, and herbal supplement you are taking or have recently taken.
Because erlotinib is used in patients with cancer who frequently have multiple comorbidities and polypharmacy – for example, proton pump inhibitors for acid reflux, anti-epileptic drugs, antifungals for infection prophylaxis, anticoagulants for thrombosis, and complementary products such as St John’s wort – drug-interaction review is one of the most important steps at the start of therapy and whenever a new medicine is added.
Major Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Ketoconazole, itraconazole, voriconazole, posaconazole and other strong CYP3A4 inhibitors | Substantial increase in erlotinib plasma concentrations (AUC may rise by 60–80%) | Avoid combination; if unavoidable, reduce erlotinib dose (e.g. from 150 mg to 100 mg) and monitor closely for toxicity |
| Clarithromycin, telithromycin, ritonavir, cobicistat (strong CYP3A4 inhibitors) | Markedly increased erlotinib exposure and risk of diarrhea, rash, hepatotoxicity | Use alternative antibiotics or antiretrovirals if possible; otherwise close clinical monitoring and dose reduction |
| Rifampicin, rifabutin (strong CYP3A4 inducers) | Decreased erlotinib AUC by up to 60%, potentially reducing anticancer efficacy | Avoid combination; dose increase (up to 300 mg/day) may be considered only with specialist oversight and safety monitoring |
| Phenytoin, carbamazepine, phenobarbital (antiepileptic enzyme inducers) | Decreased erlotinib plasma levels; reduced efficacy | Select alternative anti-epileptic agents (e.g. levetiracetam) where clinically appropriate |
| St John’s wort (Hypericum perforatum) | Potent CYP3A4 induction; decreased erlotinib exposure and efficacy | Contraindicated; do not use concomitantly |
| Proton pump inhibitors (omeprazole, esomeprazole, pantoprazole, lansoprazole) | Sustained increase in gastric pH reduces erlotinib solubility and absorption; AUC may decrease by 30–50% | Avoid if possible; PPIs cannot be reliably separated in time from erlotinib due to long duration of acid suppression |
| Warfarin and other coumarin anticoagulants | INR elevations and bleeding events have been reported | Monitor INR closely; consider more frequent measurements, especially at initiation and dose changes |
Moderate and Minor Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Histamine H2-receptor antagonists (ranitidine, famotidine) | Moderate reduction in erlotinib AUC due to gastric acid suppression | If needed, take erlotinib at least 2 hours before or 10 hours after the H2-blocker |
| Antacids (aluminium hydroxide, magnesium hydroxide, calcium carbonate) | Short-term reduction in erlotinib absorption | Separate dosing by at least several hours from erlotinib |
| Ciprofloxacin (moderate CYP1A2 and CYP3A4 inhibitor) | Increased erlotinib exposure (AUC up to ~40% higher) | Monitor for toxicity; consider alternative antibiotics |
| Grapefruit juice / Seville orange | Inhibit intestinal CYP3A4, increasing erlotinib exposure | Avoid during treatment |
| Capecitabine | Small increases in erlotinib exposure | Generally managed with standard monitoring |
| Statins (e.g. simvastatin, atorvastatin) | Possible additive hepatotoxicity in susceptible patients | Monitor liver function tests; adjust if transaminases rise |
| Cigarette smoking (not a drug, but a CYP1A2 inducer) | Up to 60% reduction in erlotinib plasma levels | Smoking cessation strongly advised before and during treatment |
When Tarceva is used in combination with gemcitabine for pancreatic cancer, no clinically meaningful pharmacokinetic interaction between the two drugs has been observed. However, overlapping toxicities – particularly rash, diarrhea, and hepatic enzyme elevations – are more frequent than with either agent alone and require careful monitoring.
What Is the Correct Dosage of Tarceva?
Tarceva is a once-daily oral medication supplied as film-coated tablets in three strengths – 25 mg, 100 mg, and 150 mg – which allow flexible dosing and stepwise reductions when side effects arise. Tablets are swallowed whole with a glass of water and must be taken on an empty stomach: at least 1 hour before, or at least 2 hours after, any food. This is because food approximately doubles the bioavailability of erlotinib, which can cause toxic plasma concentrations if the drug were taken with meals. Try to take Tarceva at the same time each day, ideally in the morning or at bedtime.
Non-Small Cell Lung Cancer
NSCLC – First-Line (EGFR Mutation-Positive), Maintenance, or Later Lines
Dose: 150 mg once daily
How to take: Swallow whole with water on an empty stomach – at least 1 hour before or 2 hours after food
Duration: Treatment is continued until disease progression or unacceptable toxicity
EGFR testing (first-line): An activating EGFR mutation (exon 19 deletion or L858R substitution is required before starting first-line therapy)
Metastatic Pancreatic Cancer
Tarceva + Gemcitabine for Metastatic Pancreatic Cancer
Dose: 100 mg once daily
Partner drug: Gemcitabine is given by intravenous infusion according to standard protocols for metastatic pancreatic cancer
Assessment: If no skin rash develops within 4–8 weeks, reassess the benefit of continuing erlotinib, since response is strongly associated with rash development in this indication
Dose Adjustments and Modifications
Dose reductions of Tarceva are typically performed in 50 mg steps (for NSCLC: 150 → 100 → 50 mg; for pancreatic cancer: 100 → 50 mg). The 25 mg tablet is particularly useful when physicians wish to titrate doses (e.g. 125 mg or 75 mg) or to use a dose-lowering strategy for patients who experience intolerable side effects.
| Toxicity | Action |
|---|---|
| Severe (Grade 3) rash | Interrupt treatment until resolved to ≤ Grade 1–2, then resume at the same or reduced dose depending on tolerance |
| Severe (Grade 3+) diarrhea not controlled by loperamide | Interrupt until resolved; rehydrate; resume at a reduced dose |
| Suspected interstitial lung disease | Immediately stop Tarceva; investigate; permanently discontinue if ILD is confirmed |
| Transaminases >3x ULN or bilirubin >3x ULN | Interrupt until values normalise; resume cautiously at a reduced dose |
| Severe ocular symptoms / corneal ulceration | Interrupt; ophthalmology review; discontinue if corneal perforation occurs |
| Gastrointestinal perforation | Permanently discontinue |
Special Populations
- Elderly (≥65 years): No specific dose adjustment is required based on age alone, but older patients may be more susceptible to dehydration from diarrhea and to hepatic or renal toxicity. Close clinical monitoring is recommended.
- Hepatic impairment: Mild to moderate hepatic impairment does not usually require an initial dose reduction, but liver function tests should be monitored frequently, and interruption or dose reduction may be needed if bilirubin rises significantly. Severe hepatic impairment is generally a contraindication.
- Renal impairment: Erlotinib is predominantly eliminated by hepatic metabolism and biliary/faecal excretion. No dose adjustment is routinely required for renal impairment, but dehydration from gastrointestinal toxicity must be prevented.
- Smokers: If smoking cessation is not achievable, a carefully supervised dose increase up to 300 mg/day has been used in clinical studies; however, toxicity can escalate rapidly if smoking subsequently stops, and the approach requires close specialist supervision.
Children
Tarceva is not approved for use in children or adolescents below 18 years of age. Safety and efficacy have not been established in the paediatric population.
Missed Dose
If you miss a dose of Tarceva, do not take a double dose. If the next scheduled dose is more than 12 hours away, take the missed dose as soon as you remember (on an empty stomach) and then resume your normal schedule. If the next dose is due within 12 hours, skip the missed dose and take only the next scheduled dose. Do not take two tablets at once to make up for a missed dose.
Overdose
Daily oral doses of erlotinib up to 1,000 mg in healthy volunteers and up to 1,600 mg as a single dose in cancer patients have been studied. Repeated twice-daily doses of 200 mg were poorly tolerated. Symptoms of overdose are extensions of the known side effects: severe diarrhea, rash, liver dysfunction, and dehydration. There is no specific antidote. Treatment involves stopping Tarceva, supportive care (rehydration, anti-diarrheal therapy, management of rash), and monitoring of liver function. Seek urgent medical advice if you suspect an overdose.
What Are the Side Effects of Tarceva?
Like all medicines, Tarceva can cause side effects, though not everyone will experience them. The type, frequency, and severity of side effects depend on the dose, the indication (NSCLC or pancreatic cancer), whether the drug is used alone or with chemotherapy, and individual patient factors such as smoking status and other medications. Early recognition and proactive management of side effects are critical to maintain treatment and quality of life.
The side effects below are grouped by frequency category, as defined in the European Medicines Agency’s Summary of Product Characteristics. Many of these reactions are dose-dependent and improve with dose interruption or reduction.
Very Common
May affect more than 1 in 10 people
- Skin rash (acneiform eruption, typically on face, scalp, upper chest, and back; usually appears within the first 2 weeks)
- Diarrhea (often mild-to-moderate, but can be severe)
- Loss of appetite (anorexia)
- Fatigue (tiredness, weakness)
- Dry skin (xerosis)
- Itching (pruritus)
- Nausea, vomiting
- Abdominal pain, indigestion
- Mouth sores or ulcers (stomatitis, mucositis)
- Infection (including eye infections, respiratory tract infections)
- Eye irritation – dry eye, conjunctivitis, keratoconjunctivitis sicca
- Shortness of breath (dyspnea)
- Cough
- Headache
- Weight loss
- Depression
- Elevated liver transaminases (ALT, AST) and bilirubin
Common
May affect up to 1 in 10 people
- Gastrointestinal bleeding (in combination with warfarin or in patients on NSAIDs)
- Paronychia (nail fold inflammation), nail disorders, brittle nails, nail splitting
- Hair changes – hair thinning, altered texture, trichomegaly (long eyelashes)
- Keratitis (inflammation of the cornea)
- Rigors (shaking chills)
- Nose bleeds (epistaxis)
- Alopecia (hair loss, usually mild)
Uncommon
May affect up to 1 in 100 people
- Hirsutism (excessive hair growth)
- Changes in eyelashes or eyebrows
- Liver failure (rarely leading to hepatorenal syndrome or death)
- Severe bullous, blistering, or exfoliative skin conditions
- Corneal ulceration
Rare
May affect up to 1 in 1,000 people
- Gastrointestinal perforation
- Corneal perforation
- Stevens-Johnson syndrome / toxic epidermal necrolysis (very severe skin and mucous-membrane reactions)
- Hand-foot syndrome (palmar-plantar erythrodysesthesia, mainly in combination regimens)
Very Rare
May affect up to 1 in 10,000 people
- Severe acute hepatic failure
Not Known
Frequency cannot be estimated from available data
- Interstitial lung disease / pneumonitis (including fatal cases, overall frequency around 1% across indications)
- Hair and nail changes unrelated to standard grading
Managing the Most Common Side Effects
Acneiform rash: This is the hallmark side effect of EGFR inhibitors and, paradoxically, is often a marker of effective EGFR blockade and better treatment response. Practical measures include using gentle, alcohol-free skincare products, applying broad-spectrum sunscreen (SPF 30+) daily, avoiding irritating cosmetics, and using emollient moisturisers. For moderate rash, topical antibiotics (e.g. clindamycin) and mild corticosteroids may be prescribed. For severe rash, systemic tetracyclines (doxycycline or minocycline) for 4–8 weeks are often effective, and dose interruption may be necessary.
Diarrhea: Starting loperamide at the first loose stool, maintaining good hydration, and avoiding lactose, caffeine, and spicy foods usually controls mild-to-moderate diarrhea. Severe or persistent diarrhea (>6 stools per day above baseline, nocturnal symptoms, dehydration) requires dose interruption, rehydration, and medical evaluation for infection.
Eye symptoms: Dry eye is common; preservative-free artificial tears are first-line. Patients who wear contact lenses may need to switch to glasses during treatment. Any eye pain, red eye, light sensitivity, or blurred vision requires prompt ophthalmological assessment to exclude keratitis or corneal ulceration.
If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed above. Reporting suspected side effects helps regulatory authorities monitor the safety of medicines. You can also report side effects directly to your national pharmacovigilance programme (e.g. the FDA MedWatch in the United States, the Yellow Card scheme in the United Kingdom, or EMA EudraVigilance in the European Union).
How Should Tarceva Be Stored?
Correct storage preserves the quality and effectiveness of Tarceva. Because it is an oral medication taken at home, patients are responsible for storing it safely.
- Temperature: Store below 30°C. The tablets do not require refrigeration.
- Packaging: Keep the tablets in the original blister pack and outer carton until they are taken, as this protects them from moisture and light.
- Children: Store out of the sight and reach of children. Accidental ingestion of a cytotoxic agent can be very dangerous.
- Expiry date: Do not use Tarceva after the expiry date (EXP) printed on the carton and blister. The expiry date refers to the last day of the stated month.
- Disposal: Do not dispose of unused or expired Tarceva via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
If a tablet is accidentally broken, dropped, or exposed to high humidity, do not take it; return it to the pharmacy for safe disposal and use the next intact tablet.
What Does Tarceva Contain?
Understanding what Tarceva contains is important for identifying potential allergens and for patients with dietary restrictions.
Active Substance
- Erlotinib (as erlotinib hydrochloride). Each tablet contains either 25 mg, 100 mg, or 150 mg of erlotinib.
Inactive Ingredients (Excipients)
Tablet core:
- Lactose monohydrate
- Microcrystalline cellulose (E460)
- Sodium starch glycolate, type A
- Sodium lauryl sulfate
- Magnesium stearate
Film-coat:
- Hypromellose
- Hydroxypropyl cellulose
- Titanium dioxide (E171)
- Macrogol (polyethylene glycol)
- Talc
Appearance and Pack Sizes
Tarceva film-coated tablets are white to yellowish, round (25 mg) or round biconvex (100 mg, 150 mg) tablets. Each tablet is debossed with “T 25”, “T 100”, or “T 150” on one side to indicate the strength. Tablets are supplied in blister packs, typically containing 30 tablets per carton.
Marketing Authorization
Tarceva is marketed by Roche Registration GmbH in the European Union and by Genentech/OSI Pharmaceuticals in the United States. The drug is also available from multiple generic manufacturers following patent expiration in many countries. Generic erlotinib products have been shown to be bioequivalent to the originator Tarceva and are prescribed interchangeably under the brand’s international nonproprietary name (INN), erlotinib.
Frequently Asked Questions About Tarceva
First-line Tarceva for non-small cell lung cancer is only effective in tumours that carry an activating EGFR mutation (most commonly exon 19 deletions or the L858R point mutation in exon 21). In patients whose tumours lack these mutations, the response rate is much lower and chemotherapy or immunotherapy is more effective. Modern guidelines therefore recommend routine EGFR mutation testing on tumour tissue or, when tissue is unavailable, on circulating tumour DNA from a blood sample, before choosing first-line therapy. Skipping this testing can mean missing a far more effective targeted therapy or using Tarceva where it will not work.
Multiple clinical studies have shown that patients who develop a Tarceva-induced acneiform rash, especially moderate to severe rash, tend to have better response rates and longer survival than patients who develop little or no rash. This link is thought to reflect effective EGFR inhibition in the skin, suggesting adequate drug exposure. However, rash is not a perfect marker, and the goal is not to cause severe rash – supportive skin care, sun protection, and targeted therapies (such as doxycycline or topical antibiotics) are important. The absence of rash does not automatically mean the drug is failing, especially in EGFR-mutation-positive lung cancer.
You should discuss this with your oncologist. Proton pump inhibitors (such as omeprazole, esomeprazole, pantoprazole, and lansoprazole) reduce gastric acidity and can lower erlotinib absorption by 30–50%, potentially reducing its effectiveness. Because the effect of PPIs on gastric pH lasts most of the day, you cannot simply separate the dosing times. If acid reflux treatment is necessary, your oncologist may switch you to an H2-blocker (ranitidine or famotidine) taken at least 2 hours before or 10 hours after erlotinib, or to an antacid that can be separated in time. Always tell your doctor about any over-the-counter heartburn medications you are taking.
Mild to moderate diarrhea can usually be managed with over-the-counter loperamide (starting with 4 mg, then 2 mg after each loose stool, up to a maximum daily dose), good hydration (aim for 2–3 litres of clear fluids per day), and dietary modifications such as avoiding caffeine, alcohol, lactose, and spicy foods. If you have more than 6 stools per day above your normal baseline, nocturnal diarrhea, blood in the stool, severe abdominal pain, fever, or signs of dehydration (dizziness on standing, dark urine, dry mouth), contact your medical team immediately. They may temporarily stop Tarceva, provide intravenous fluids, rule out infection, and resume treatment at a lower dose.
Tarceva is metabolised extensively by the liver, and significant hepatic impairment increases the risk of severe toxicity. Hepatitis (including fatal cases) and hepatorenal syndrome have been reported with erlotinib. If you have any history of hepatitis B, hepatitis C, cirrhosis, or other liver disease, tell your oncologist before starting treatment. Baseline and periodic liver function tests (typically every 4–8 weeks) are essential. Patients with chronic hepatitis B may need antiviral prophylaxis because systemic therapy can trigger viral reactivation. In severe hepatic impairment, Tarceva is generally contraindicated; in mild to moderate impairment it may still be used, but with careful monitoring and often a lower starting dose.
Most patients with EGFR-mutation-positive NSCLC who initially respond to Tarceva will eventually develop resistance, typically after 9–14 months. The most common mechanism is the acquisition of a second EGFR mutation called T790M, which decreases erlotinib binding. When progression occurs, your oncologist will typically arrange a new tumour biopsy or a blood test (“liquid biopsy” for circulating tumour DNA) to identify the resistance mechanism. If T790M is detected, third-generation EGFR inhibitors such as osimertinib are highly effective and have become the standard of care. In many settings, osimertinib is now used as the preferred first-line EGFR inhibitor, but Tarceva remains an important option depending on availability, tolerability, and local guidelines.
Generic erlotinib products approved by the EMA, the FDA, and other regulatory agencies are required to demonstrate bioequivalence to the originator Tarceva, meaning they deliver the same amount of active drug to the bloodstream in the same time frame. In clinical practice, generic and branded erlotinib are used interchangeably in many countries. Always take the specific product prescribed by your oncologist, follow the same empty-stomach administration rules, and be aware that the tablet appearance (shape, colour, debossed marking) may differ between manufacturers. If you have any concerns about a change from Tarceva to a generic, discuss them with your pharmacist or oncologist.
References
- European Medicines Agency (EMA). Tarceva – Summary of Product Characteristics (SmPC). Last updated 2025. Available at: ema.europa.eu/en/medicines/human/EPAR/tarceva
- U.S. Food and Drug Administration (FDA). Tarceva (erlotinib) tablets – Prescribing Information. Last updated 2024.
- Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. New England Journal of Medicine. 2005;353(2):123-132. doi:10.1056/NEJMoa050753
- Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology. 2007;25(15):1960-1966. doi:10.1200/JCO.2006.07.9525
- Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology. 2012;13(3):239-246. doi:10.1016/S1470-2045(11)70393-X
- Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study (SATURN). Lancet Oncology. 2010;11(6):521-529. doi:10.1016/S1470-2045(10)70112-1
- Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised phase 3 study. Lancet Oncology. 2011;12(8):735-742. doi:10.1016/S1470-2045(11)70184-X
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 2025.
- European Society for Medical Oncology (ESMO). Clinical Practice Guidelines: Metastatic Non-Small Cell Lung Cancer. Annals of Oncology 2024.
- Hamilton M, Wolf JL, Rusk J, et al. Effects of smoking on the pharmacokinetics of erlotinib. Clinical Cancer Research. 2006;12(7 Pt 1):2166-2171. doi:10.1158/1078-0432.CCR-05-2235
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List, 2023. Geneva: World Health Organization.
Editorial Team
Medical Content
iMedic Medical Editorial Team – Specialists in Oncology and Clinical Pharmacology
Medical Review
iMedic Medical Review Board – Independent panel following WHO, EMA, and FDA guidelines
Evidence Level
Level 1A – Based on systematic reviews, meta-analyses, and randomized controlled trials
Last Reviewed
– Updated according to current EMA SmPC and FDA prescribing information
All medical content on iMedic is written and reviewed by qualified healthcare professionals following the GRADE evidence framework. We adhere to strict editorial standards with no commercial funding or pharmaceutical sponsorship. For questions or corrections, please contact our editorial team.